$35.3MSeed, 3 November 2026
SRTD Biotech completed a €31.5 million Seed round led by Mérieux Equity Partners and co-led by NRW.BANK and Boehringer Ingelheim Venture Fund to develop precision mRNA therapeutics.
- Amount
- $35.3M
- Stage
- Seed
- Announced
- 3 November 2026
- Leads
- Mérieux Equity Partners, NRW.BANK, Boehringer Ingelheim Venture Fund
- Other investors
- Lilly Ventures, HTGF, Anobis Asset
- Use of funds
- Advance preclinical development of its pipeline of novel targeted RNA therapies
- Checked
- Amount and date checked against the press source
- Source
- Jülich-based SRTD Biotech secures €31.5 million to develop precision mRNA therapies targeting diseased cells eu-startups.com